Search Results
Your search for ,WHo matches 20189 pages
Showing 3901 - 3950Multiple Myeloma: Treatment Conundrums
The availability of numerous new agents for treating multiple myeloma has created some “conundrums” for clinicians, said Sergio Giralt, MD, Deputy Head of the Division of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center and the Melvin Berlin Family Chair in Myeloma Research and...
Rise of Esophageal Cancer and Barrett’s Esophagus Rates in Middle-Aged Adults
Adults aged 45 to 64 years experienced a nearly doubled rate of esophageal cancer and a 50% increase in the precancerous condition Barrett’s esophagus between 2012 and 2019, according to a database analysis of roughly 5 million patients presented by Qumseya et al at Digestive Disease Week 2022...
Persistent Racial, Ethnic Disparities Found in Survival Rates for Early-Onset Colon Cancer
The 5-year survival for younger adults with colorectal cancer improved for White patients alone between 1992 and 2013, according to a new analysis presented by Zaki et al at Digestive Disease Week 2022 (Abstract 895). However, no survival gains were found for Black, Hispanic, or Asian patients with ...
Study Finds State Public Welfare Spending Was Associated With Improved 5-Year Overall Survival in Black Patients With Cancer
According to a recent report by The Commmonwealth Fund, “large racial and ethnic health inequities, driven by factors both inside and outside the health-care delivery system [in the United States], are common.” The result, according to the report, is that actions that could mitigate health...
Nearly Half of Black Patients With Metastatic Breast Cancer Report Not Being Informed About Clinical Trials
A survey of patients with metastatic breast cancer found that 83% of Black respondents were somewhat or very likely to consider clinical trial participation; however, 40% of those respondents reported that they had not been informed by their care team about the opportunity to enroll in a trial. The ...
Use of Telemedicine for Cancer Care Increased During the COVID-19 Pandemic but Varied by Race, Socioeconomic Status, and Other Factors
With the rapid acceleration of the spread of the COVID-19 virus in the United States in March 2020, telemedicine visits became more common for cancer care. However, in an evaluation of telemedicine inequities among patients with 21 common cancers, there were distinctly lower levels of telemedicine...
FDA Approves Ivosidenib/Azacitidine for Certain Patients With Newly Diagnosed AML
On May 25, the U.S. Food and Drug Administration (FDA) approved ivosidenib (Tibsovo) in combination with azacitidine for patients with newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test in adults aged 75 or older, or who have...
Incidental Respiratory Disease Found in Low-Dose CT Screens: Challenges and Opportunities
A retrospective analysis of the National Lung Screening Trial (NLST) by Pinsky et al, summarized in the April 25, 2022, issue of The ASCO Post, found high rates of incidental respiratory abnormalities on low-dose computed tomography (CT) examinations.1 Specifically, the findings of emphysema and...
Representatives Diana DeGette and Fred Upton Named ASCO Congressional Champions for Cancer Care
ASCO recently presented Representatives Diana DeGette (D-CO-1) and Fred Upton (R-MI-6) with the annual Congressional Champion for Cancer Care Award in recognition of their commitment to legislation that focuses on medical innovation. The award honors members of Congress who are leading champions...
ASCO Expands Oncology Summer Internship Program With Aims to Increase Workforce Diversity
ASCO recently announced six additional medical schools will participate in the second year of the Oncology Summer Internship (OSI) program, an immersive, 4-week summer internship for rising second-year medical students from groups underrepresented in medicine (UIM).1 In 2022, ASCO and a total of 11 ...
Finding a New Normal After Classical Hodgkin Lymphoma
As every patient diagnosed with cancer knows, the disease affects not just your physical well-being, but your emotional well-being, too. I was just 35 years old when I was diagnosed with early-stage classical Hodgkin lymphoma this past summer, and the news came at a time when I was feeling in top...
An Emergency Room Physician Offers Hands-on Perspective for Treating Patients With Cancer
According to research in the literature, adults with cancer generate high rates of emergency department visits, leading to hospitalization roughly 60% of the time—nearly four times the rate of the general population. Although many of these visits could be prevented, this phenomenon offers numerable ...
Expert Point of View: David Paul Carbone, MD, PhD
“Progress in lung cancer happens by slow steps punctuated by quantum leaps. In the age of perioperative therapies, we are moving one step closer to curing more patients. Surgery is still the intervention most likely to cure patients with earlier-stage disease, but 50% of cases can recur,” said...
Long-Term Overall Survival in Unresectable Stage III NSCLC With Consolidation Durvalumab in the PACIFIC Trial: Translation to Real-World Outcomes?
Lung cancer mortality rates have declined by more than 50% in men since 1990 and more than 30% in women since 2002. These declines in mortality are largely due to increases in smoking cessation. However, in recent years, clinical treatment advances, such as targeted therapies and immunotherapy,...
PD-1 Inhibition in First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma: More to Come on New Paradigm
Esophageal cancer is associated with significant morbidity and mortality worldwide, with more than 600,000 new cases and 540,000 deaths in 2020. The squamous cell histology comprises nearly 90% of cases globally, despite its steady decline in the United States over the past 40 years. Historically,...
ASCO Sets Goals to Advance the Clinician-Educator Career Pathway in Oncology
Although most oncology program directors and associate or assistant program directors consider themselves clinician-educators, they receive little to no formal medical education training to nurture trainees into clinician-educator careers and do not have a clinician-educator track for their...
The Impact of War on Patients With Cancer
Just days after Russia invaded Ukraine on February 24, ASCO, together with its partners the American Cancer Society (ACS) and the Sidney Kimmel Cancer Center–Jefferson Health, began assembling resources to establish a network of oncology professionals to help Ukrainian patients with cancer find...
Tackling the Global Burden of Cancer on Adolescents and Young Adults With Cancer
Several recent studies examining the global burden of cancer on adolescents and young adults (AYAs) show the growing magnitude of the disease’s impact on the lives of individuals between the ages of 15 and 39. Although considered a rare occurrence, cancer in this age group has risen by...
Pembrolizumab for MSI-H/dMMR Advanced Endometrial Carcinoma
On March 21, 2022, pembrolizumab was approved for patients with advanced endometrial carcinoma that is microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR), as determined by a U.S. Food and Drug Administration (FDA)-approved test, who have disease progression following prior...
Elaine S. Jaffe, MD, Honored With Inaugural AACR James S. Ewing– Thelma B. Dunn Award for Outstanding Achievement in Pathology
At the recent American Association for Cancer Research (AACR) Annual Meeting 2022, Elaine S. Jaffe, MD, received the inaugural AACR James S. Ewing–Thelma B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research. The AACR established this new award to honor pathologists who continue ...
Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma
On April 1, 2022, axicabtagene ciloleucel was approved for adults with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.1 It is not indicated for the treatment of patients with primary central nervous system...
UC Davis Launches Center for Advancing Cancer Health Equity
To address cancer health disparities in the region, the University of California (UC) Davis Comprehensive Cancer Center is launching the Center for Advancing Cancer Health Equity, which will conduct community-engaged research and interventions using multilevel approaches. The new center will build...
How St. Jude and the WHO Are Sparking an International Movement to Increase Treatment Access for Children With Cancer
The toll of cancer on children, especially those living in low-resource countries, is staggering. Each year, an estimated 400,000 children and adolescents worldwide develop cancer,1 and despite improved survival rates, the global 5-year net childhood cancer survival rate is only 37.4%,2 making...
Surgical Approach and Overall Survival in Younger Women With Breast Cancer
More extensive surgery does not improve survival over less aggressive surgery in younger women with breast cancer, according to data presented at the 2022 American Society of Breast Surgeons Annual Meeting.1 The results of a retrospective study of nearly 600 patients showed that treatment with...
Diversity in Clinical Trials Training Program Renamed to Honor Robert A. Winn, MD
The Bristol Myers Squibb Foundation (BMSF), together with its partners National Medical Fellowships and the American Association for Cancer Research, has announced a new name for the $100 million, 5-year initiative launched in 2020 to increase diversity in clinical trials: The Robert A. Winn...
Novel Neoadjuvant Therapy May Boost Response in Resectable NSCLC
Use of multiple immune pathway inhibitors appears to be superior to checkpoint inhibitor therapy alone as neoadjuvant therapy for resectable non–small cell lung cancer (NSCLC), according to the results of the phase II NeoCOAST trial presented at the American Association for Cancer Research (AACR)...
An Early Love of Science Led to a Career in Breast Cancer Research for Sara M. Tolaney, MD, MPH
In this installment of Living a Full Life, Guest Editor Jame Abraham, MD, spoke with Sara M. Tolaney, MD, MPH, a faculty member of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, where she is Chief of the Breast Cancer Program. Her current research focuses on the development of novel ...
Combination Therapy of Olaparib, Cyclophosphamide, and Metformin Under Study in Advanced Endometrial Cancer
A triplet regimen consisting of the PARP (poly [ADP-ribose] polymerase) inhibitor olaparib, metronomic (the chronic administration of low, equally spaced doses of) cyclophosphamide, and metformin demonstrated activity in elderly, heavily pretreated patients with recurrent, advanced endometrial...
Radiation Segmentectomy for Very Early– and Early-Stage Hepatocellular Carcinoma
Radiation segmentectomy may be an effective treatment for very early– to early-stage hepatocellular carcinoma (HCC) that cannot be treated surgically or thermally. The findings from a multidisciplinary study by researchers at the Icahn School of Medicine at Mount Sinai were published by Kim et al...
Gabapentin May Be an Effective Alternative to Opioids for Patients With Head and Neck Cancer Receiving Radiation
Patients with head and neck cancer undergoing radiation therapy may be less likely to require opioids or a feeding tube if they received a higher dose of prophylactic gabapentin before their treatment, findings from a team of radiation oncologists showed. Their report, published by Ma et al in JAMA ...
Does Treatment With 5α-Reductase Inhibitors Impact the Risk of Dying of Prostate Cancer Among Men Without a Prior Diagnosis of the Disease?
In a Swedish study reported in JAMA Oncology, Björnebo et al found that longer use of 5α-reductase inhibitors (5-ARIs) for the treatment of benign prostatic hyperplasia was associated with a reduced risk of prostate cancer mortality among men without a prior diagnosis of prostate cancer. As stated...
Mario Sznol, MD, and Stefania Scala, MD, on Improving Responses to Immunotherapy in Patients With Melanoma
Invited study discussant of the use of ipilimumab plus nivolumab in resistant melanoma, at the AACR Annual Meeting 2022, Mario Sznol, MD, of Yale University Cancer Center, indicated that the substantial increase in progression-free survival at 6 months was not maintained. “The durable...
Approaches to Potentiate Immune Response in Patients Who Do Not Respond to Anti–PD-1 Therapy for Melanoma
A sizable proportion of patients with advanced melanoma will experience disease progression on anti–PD-1 therapy, and the optimal treatment of such patients represents an unmet need. Two studies presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 explored separate...
EMERALD Trial: Elacestrant vs Standard Endocrine Therapy in Previously Treated Patients With ER-Positive, HER2-Negative Advanced Breast Cancer
As reported in the Journal of Clinical Oncology by François-Clément Bidard, MD, PhD, and colleagues, the phase III EMERALD trial has shown prolonged progression-free survival with the oral selective estrogen receptor (ER) degrader elacestrant vs standard endocrine therapy among patients with...
Tazemetostat for Patients With Relapsed or Refractory BAP1-Inactivated Malignant Pleural Mesothelioma
In a phase II study reported in The Lancet Oncology, Zauderer et al found that the EZH2 inhibitor tazemetostat was active in patients with relapsed or refractory BRCA-associated protein 1 (BAP1)-inactivated malignant pleural mesothelioma. As noted by the investigators, high expression of EZH2 has...
Adverse Events Seen With Abiraterone or Enzalutamide Among Patients With Advanced Prostate Cancer
Men taking either of the two most common oral medications for advanced prostate cancer who had also undergone hormone therapy to treat their disease were at higher risk of serious metabolic or cardiovascular issues than patients who were receiving hormone therapy alone, according to findings...
Report Examines Imaging Approach With Potential to Detect Lung Cancer at the Cellular Level
Researchers have found a way to identify lung cancer at the cellular level in real time during a biopsy, which may enable detection of the disease earlier and with more confidence. The findings, published by Kennedy et al in Nature Communications, demonstrated that an imaging agent detected via...
Reports From the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer
The Society of Gynecologic Oncology Annual Meeting on Women’s Cancer was held recently in Phoenix, Arizona. On this episode, we’ll hear from two researchers who presented data at the meeting on ovarian and cervical cancers.
Drug Developers Share Thoughts on the Oncology Pipeline and the Changes in Clinical Trials
Two oncologists who are now heads of oncology development for pharmaceutical companies discussed the future of cancer drugs at the Community Oncology Alliance’s 2022 Community Oncology Conference. They were Johanna Bendell, MD, Global Head of Oncology, Pharma Research, and Early Development at...
Researchers Develop and Monitor Approaches to Fix Blood Vessel Abnormalities That Make Tumors Difficult to Treat
Tumors send out signals that impair normal blood flow, which makes them hard to treat with multiple therapies, including radiation, chemotherapy, targeted therapies, and immunotherapy. Impaired blood supply creates an environment low in oxygen levels, which causes the tumors to take on aggressive...
ASCO and ACCC Release Wide-Ranging Recommendations to Expand Diverse Participation in Cancer Clinical Trials
ASCO and the Association of Community Cancer Centers (ACCC) have jointly released recommendations that address the lack of equity, diversity, and inclusion in cancer clinical trials. Published by Randall A. Oyer, MD, and colleagues in the Journal of Clinical Oncology, the research statement details ...
Intraoperative Margin Assessment in Breast-Conserving Surgery Using a Pegulicianine Fluorescence–Guided System
In the INSITE study reported in JAMA Surgery, E. Shelley Hwang, MD, MPH, and colleagues found that use of an intraoperative imaging agent with a pegulicianine fluorescence–guided system (pFGS) was effective in detecting residual cancer in the tumor bed of women with breast cancer undergoing...
Surgery Preference and Surgery Received in Women With DCIS
In an ancillary study of the ECOG-ACRIN Cancer Research Group E4112 study reported in JAMA Network Open, Fazeli et al found that patient preference of type of surgery and type of surgery received for ductal carcinoma in situ (DCIS) were influenced by preoperative magnetic resonance imaging (MRI)...
NCCN Clinical Practice Guidelines in Oncology: 2022 Updates
In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology® covering eight tumor types. Guidelines are now published for more than 60 tumor types, subtypes, and topics. During the NCCN’s 27th Annual Conference, which was again...
Etirinotecan Pegol vs Physician’s Choice of Chemotherapy for Patients With Metastatic Breast Cancer and Brain Metastases
As reported in JAMA Oncology by Debu Tripathy, MD, and colleagues, the phase III ATTAIN trial has shown no difference in overall survival with etirinotecan pegol vs physician’s choice of chemotherapy for patients with metastatic breast cancer and brain metastases. As noted by the investigators,...
Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Multifocal Intrahepatic Cholangiocarcinoma
In a cohort study reported in JAMA Surgery, Franssen et al found little difference in median overall survival with hepatic arterial infusion pump (HAIP) floxuridine chemotherapy vs resection in patients with multifocal intrahepatic cholangiocarcinoma. Study Details The study population consisted of ...
The Future of Community Oncology Practice
Although community oncology practice may have been changing before the COVID-19 pandemic, it amplified industry trends. At the 2022 Community Oncology Alliance’s Community Oncology Conference, a panel of experts discussed issues related to the future of community cancer care, including...
Longer Follow-up Shows Adjuvant Immunotherapy After Bladder Cancer Surgery May Be Associated With Reduced Disease Recurrence
Treatment with the anti–PD-1 therapy nivolumab after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle and therefore posed a high risk for recurrence, according to clinical trial results...
Study Investigates Possible Link Between Risk of Breast Cancer in Males and Male Infertility
The risk of invasive breast cancer in men may be associated with self-reported infertility, according to a study published by Swerdlow et al in the journal Breast Cancer Research. The authors interviewed 1,998 males in England and Wales diagnosed with breast cancer, with 112 (5.6%) also...
Early Postoperative Algorithm-Based vs Usual Care After Pancreatic Resection
In a Dutch nationwide trial reported by Smits et al in The Lancet, researchers in the Dutch Pancreatic Cancer Group found that algorithm-based early postsurgical care was associated with a reduced risk of the composite outcome of bleeding requiring invasive intervention, organ failure, and 90-day...
